Latest News

Jehoshaphat Research’s short report on GPGI (GPGI), centered on alleged overstatement of Husky Technologies’ financial metrics and the abrupt CEO and CFO resignations, has quickly become a key focus for traders assessing the stock. See our latest analysis for GPGI. GPGI’s latest short report comes after a year where the share price has moved sharply at times, with a 20.25% year to date share price return and a very large 3 year total shareholder return of about 4x. This is even with a recent...

Traton (XTRA:8TRA) shares are back in focus after the company extended the contract of key executive Antonio Roberto Cortes, a leadership decision that may influence future operations and long-term planning. See our latest analysis for Traton. At a share price of €36.04, Traton has seen a 9.41% 1 month share price return and 26.10% 3 month share price return. The 3 year total shareholder return of 144.24% and 5 year total shareholder return of 68.69% point to stronger longer term momentum...

In late February 2026, Mirum Pharmaceuticals reported Q4 2025 revenue of US$148.93 million and a quarterly net loss of US$5.73 million, alongside filing shelf registrations to potentially issue up to 12,074,780 new common shares worth about US$1.30 billion. While these results showed a smaller annual net loss of US$23.36 million on full-year revenue of US$521.31 million, the large prospective equity issuance raised fresh questions about dilution and how Mirum plans to finance its ongoing...

WEBTOON Entertainment (WBTN) is back in focus as markets weigh expectations for its upcoming earnings, with forecasts pointing to a quarterly loss and year over year declines in revenue and several key business segments. See our latest analysis for WEBTOON Entertainment. At a latest share price of $11.25, WEBTOON Entertainment has a 1 year total shareholder return of 26.4%, while its year to date share price return of 14.8% and 90 day share price return of 19.1% suggest momentum has cooled...

In February 2026, The Allstate Corporation declared approximately US$29.3 million in cash dividends on its Series H, I and J preferred stock for the January 15 to April 14 period, payable on April 15 to stockholders of record on March 31, alongside board approval of a higher quarterly common dividend of US$1.08 per share. This combination of stronger earnings, improved auto and homeowners loss ratios, and increased common and preferred dividends underlines management’s confidence in the...

Elemental Royalty Corporation previously announced that its Board of Directors approved an inaugural dividend policy, targeting an annual cash dividend of US$0.12 per common share, paid quarterly in instalments of US$0.03 starting with the first calendar quarter of 2026. This first-time commitment to recurring cash returns marks a shift in Elemental Royalty’s capital allocation approach and may broaden its appeal to income-focused investors. With this new regular dividend framework in place,...

Green Brick Partners, Inc. reported fourth-quarter 2025 revenue of US$552.61 million and net income of US$78.37 million, with full-year revenue of about US$2.10 billion and net income of US$313.23 million, while its board authorized a new US$150 million share repurchase program and continued quarterly dividends on its Series A preferred stock. Despite year-on-year declines in quarterly and full-year earnings per share, Green Brick posted record fourth-quarter home deliveries and net orders,...

CLP Holdings (SEHK:2) shares are in focus after the company reported weaker expected 2025 earnings alongside a higher dividend, lifting the total payout to HK$3.20 per share and raising its fourth interim dividend to HK$1.31. See our latest analysis for CLP Holdings. At a share price of HK$74.15, CLP Holdings has seen short term share price pressure with a 7 day share price return decline of 4.2%. Its 90 day share price return of 9.37% and 1 year total shareholder return of 20.75% point to...

Tarsus Pharmaceuticals (TARS) recently reported full year 2025 results, with revenue of US$451.36 million and a net loss of US$66.42 million, and also filed a US$141.73 million shelf registration. See our latest analysis for Tarsus Pharmaceuticals. The latest earnings improvement and governance changes appear to sit behind a strong share price recovery, with a 30 day share price return of 17.01% and a one year total shareholder return of 76.78%. This is despite the year to date share price...

In February 2026, Copart, Inc. reported that its second-quarter revenue slipped to US$1,121.67 million from US$1,163.32 million a year earlier, with net income easing to US$350.73 million and diluted earnings per share from continuing operations at US$0.36 versus US$0.40. An interesting contrast is that while quarterly revenue and profit dipped year over year, Copart’s net income for the first half of the fiscal year edged up slightly to US$754.45 million, with earnings per share essentially...

Castellum (OM:CAST) has come under closer scrutiny after reporting a quarterly net loss along with a year over year revenue dip, while the Board also proposed no cash dividend for the 2025 financial year. See our latest analysis for Castellum. Despite the quarterly loss and the proposed halt to cash dividends, Castellum’s recent share price momentum has been positive, with a 1 month share price return of 9.13% and a 1 year total shareholder return of 4.30%. However, the 5 year total...

On 27 February 2026, Mowi ASA announced that Chair of the Board Ørjan Svanevik resigned with immediate effect, with Vice Chair Leif Teksum stepping in as Intermediate Chair following Svanevik’s departure from associated company Seatankers Management. Teksum’s extensive background in seafood-sector banking and board roles across major Norwegian companies may reassure investors about governance continuity during this leadership transition. We’ll now examine how Teksum’s appointment as...

EXEO Group’s latest share buyback activity EXEO Group (TSE:1951) recently reported repurchasing 140,400 shares in February 2026, spending about ¥408 million as part of an ongoing buyback program that runs through June 2026. The authorization allows EXEO Group to acquire up to 2,000,000 shares or ¥4 billion in total. Management has linked this program to its aim of supporting earnings per share and refining the company’s capital structure. See our latest analysis for EXEO Group. EXEO Group’s...

QuidelOrtho (QDEL) has drawn fresh investor attention after announcing a long-term supply agreement with Lifotronic Technology, giving the diagnostics company access to additional immunoassay analyzers and more than 70 assays across select markets outside the United States. See our latest analysis for QuidelOrtho. That supply agreement arrives at a time when QuidelOrtho’s share price has seen a 7.31% 7 day gain to US$22.74, but its year to date share price return of 20.99% and 1 year total...

Oil price shock and policy backdrop put PetroChina in focus A sharp jump in global oil prices following the Iran conflict, combined with Beijing’s policy support ahead of the National People’s Congress, has pushed PetroChina (SEHK:857) into the spotlight for many investors. See our latest analysis for PetroChina. The latest oil shock has arrived on top of an already strong run, with PetroChina’s share price at HK$9.93, a 30 day share price return of 7% and year to date share price return of...

Earnings and leadership changes draw focus to Erie Indemnity (ERIE) Erie Indemnity (ERIE) has moved into the spotlight after releasing its full year 2025 results, showing revenue of US$4,067.26 million alongside lower net income and earnings per share compared with the prior year. See our latest analysis for Erie Indemnity. Investors have been weighing the full year 2025 results and the planned CEO transition against recent market performance, with the share price at US$269.44 and a 1 year...

Aehr Test Systems recently announced a US$14,000,000 order from its lead AI processor customer for multiple fully automated FOX-XP wafer-level test and burn-in systems, WaferPak contactors, and Auto Aligners to support data center AI applications, with shipments expected within six months. This deal expands the customer’s automated wafer-level burn-in capacity and underscores Aehr’s role in providing reliability-focused test equipment for high-power AI processors. We’ll now examine how this...

In late February 2026, Sally Beauty Holdings faced renewed investor scrutiny as hotter-than-expected US wholesale inflation data raised concerns that rising input costs could pressure consumer spending on discretionary beauty products and weigh on specialty retailers like the company. At the same time, Sally Beauty’s decision to deepen its Rooted in Success HBCU campus tour underscores a push to build brand loyalty and community ties among younger, diverse consumers even as its mature store...

Organizational overhaul puts Fuyo General Lease (TSE:8424) in focus Fuyo General Lease (TSE:8424) is drawing investor attention after announcing an organizational overhaul planned for April 2026 that will add new energy and risk units and reshape its real estate and regional divisions. The company is also promoting and appointing executives across corporate, financial, real estate, ICT, and compliance functions, aiming to align management responsibilities more closely with its core leasing,...

Systena Corporation recently reported the finalized financial results of its unlisted parent, SMS Holdings Corporation, which showed a solid FY2025 financial position supported by non-operating income despite an operating loss. Because SMS Holdings owns about 29% of Systena and shares leadership, this disclosure sheds light on the financial strength of Systena’s controlling shareholder and its governance linkages. Next, we’ll explore how SMS Holdings’ revealed financial stability and close...

Galaxy Entertainment Group (SEHK:27) is back in focus after reporting full year 2025 results together with a higher recommended final dividend, a combination that is drawing fresh attention to the stock. See our latest analysis for Galaxy Entertainment Group. The share price has been choppy around the HK$40.12 level, with a 1 day share price return of a 3.93% decline and a 7 day share price return of an 8.40% decline. However, the 1 year total shareholder return of 28.16% contrasts with...

Zimplats Holdings (ASX:ZIM) has put fresh numbers on the table, releasing interim results for the half year to 31 December 2025 that show higher sales, profit and earnings per share. See our latest analysis for Zimplats Holdings. The latest interim earnings release appears to have shifted sentiment, with a 3.78% 1 day share price return and 9.00% 7 day share price return, building on a 20.10% 90 day share price return and 80.60% 1 year total shareholder return, even though the year to date...

The RealReal, Inc. recently reported past fourth-quarter and 2025 results showing revenue rising to US$194.05 million for the quarter and US$692.85 million for the year, with its annual net loss narrowing to US$41.8 million as the company achieved positive adjusted EBITDA in every quarter. Alongside this profitability progress, The RealReal filed a US$77.88 million shelf registration tied to its ESOP and reopened its reimagined San Francisco flagship, underscoring how AI-enabled efficiency...

In February 2026, Takeda announced positive Phase 3 KEPLER trial results showing ENTYVIO (vedolizumab) induced clinical remission in children aged 2–17 with moderately to severely active ulcerative colitis, and said it plans regulatory submissions in the US, EU and other markets. The data highlight ENTYVIO’s potential to extend a key gastroenterology therapy into a pediatric population where treatment options are limited, reinforcing Takeda’s focus on high-need specialty indications. We’ll...